InvestorsHub Logo
Followers 14
Posts 730
Boards Moderated 0
Alias Born 12/09/2013

Re: NY1972 post# 1277

Friday, 01/15/2016 8:53:37 AM

Friday, January 15, 2016 8:53:37 AM

Post# of 2933
Well, we will see. First it has to complete phase 1 work. In that time they will scrutinize other nukes for a combo

Picking a companion nuke is a double edged sword.

A weak nuke could mean a weak combo

Sovaldi might mean success for the combo, but could make the drug less affordable.

IF ENTA could partner with or acquire a successful nuke (how many have failed here?), it could have great commercial success.


It has a long way to go, but the slides look very encouraging. There is at least one nuke available commercially (sovaldi) that could make this (potentially) a best in class treatment. I would think this could make ENTA attractive for acquisition, or to partner with.

If it has a viable POC I would think there would be plenty of suitors.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News